<DOC>
	<DOCNO>NCT01646385</DOCNO>
	<brief_summary>This study ass rate serious adverse event death adult rheumatoid arthritis patient treat etanercept long-term real-life clinical practice . It also assess whether difference rate serious adverse event patient trated etanercept comparision patient treat conventional disease-modifying anti-rheumatic drug ( DMARDs ) . The study addition quantify efficacy etanercept population assess rate important clinical outcome change disease activity disability/functioning .</brief_summary>
	<brief_title>Study Assess Safety Efficacy Etanercept Patients Treated Over Long-term Real-world Clinical Practice , Using Data Collected British Society Rheumatology Biologics Registry</brief_title>
	<detailed_description>patient recruit sequentially see clinical practice</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>adult rheumatoid arthritis group 1 : initiating etanercept first biologic therapy group 2 : DAS28 &lt; 4.2 , biologic naive treat nonbiologic DMARDs diagnosis inflammatory arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>observational</keyword>
	<keyword>non-interventional</keyword>
	<keyword>cohort</keyword>
	<keyword>retrospective</keyword>
	<keyword>register</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>